Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMENT-R: Neoadjuvant Immunotherapy Combined With Chemoradiotherapy for Rectal Cancer
NCT05507112Phase 2Active, not recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2022
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in rectal cancer, sponsored by Peking Union Medical College Hospital. Started Dec 2022; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05507112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507112.